In the third episode of our mini series on artificial intelligence, Lori and guests continue their exploratory discussion on AI and the opportunity in patient lives.
> Listen on Spotify
> Listen on Amazon Music
> Listen on iHeart
Designating something “safe” in this industry means acceptable risk. AI can help us improve acceptable risks if it is used appropriately. However, industry experts must be thoughtful and responsible in their use of AI within clinical trials.
In the third episode of our mini series on artificial intelligence, our guests explore the challenges and benefits of integrating technology into the lives of patients.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Mike King, Senior Director of Product and Strategy, IQVIA
Moritz von Stosch, Chief Innovation Officer, DataHow
Nindhana Paranthaman, Executive Medical Director, Clinical Development, Summit Therapeutics
Paul Agapow, Head of Data Science, BioNTech
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organization.
